ZTS Q3 2024 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.4B+11.0% YoY

Gross Profit

$1.7B69.2% margin

Operating Income

$920M38.5% margin

Net Income

$682M28.6% margin

EPS (Diluted)

$1.50

QoQ Revenue Growth

+1.1%

Cash Flow

Operating Cash Flow

$951M

Free Cash Flow

$784M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$14.4B

Total Liabilities

$9.1B

Stockholders' Equity

$5.2B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.2B	+11.0%
Gross Profit	$1.7B	$1.5B	+12.0%
Operating Income	$920M	$798M	+15.3%
Net Income	$682M	$596M	+14.4%

Revenue Segments

Dogs and Cats

$1.6B66%

Cattle

$391M17%

Poultry

$139M6%

Swine

$131M6%

Fish

$70M3%

Horses

$58M2%

Geographic Segments

United States Segment

$1.3B57%

International Segment

$1.0B43%